We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+0.32%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$116M
AUM Growth
–
Cap. Flow
+$123M
Cap. Flow %
105.84%
Top 10 Hldgs %
96.08%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$71.5M
2
NGNE icon
Neurogene
NGNE
+$10.7M
3
BPMC
Blueprint Medicines
BPMC
+$7.06M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$6.66M
5
ARDM
Aradigm Corp Common Stock
ARDM
+$6.39M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$63.9M 55.2%
+2,023,232
New +$71.5M
NGNE icon
2
Neurogene
NGNE
$656M
$10.1M 8.72%
+40,471
New +$10.7M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$8.26M 7.13%
+313,626
New +$7.06M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$7.18M 6.2%
+160,000
New +$6.66M
KURA icon
5
Kura Oncology
KURA
$800M
$5.5M 4.75%
+654,595
New +$5.15M
VTAE
6
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$4.53M 3.91%
+250,270
New +$3.44M
ARDM
7
DELISTED
Aradigm Corp Common Stock
ARDM
$4.37M 3.78%
+1,101,513
New +$6.39M
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$3.32M 2.86%
+225,000
New +$3.02M
EIGR
9
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.06M 1.78%
+3,111
New +$1.76M
AKTX
10
Akari Therapeutics
AKTX
$13.8M
$2.03M 1.75%
+175
New +$2.6M
SPHS
11
DELISTED
Sophiris Bio, Inc.
SPHS
$1.78M 1.54%
+1,000,000
New +$1.48M
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.69M 1.46%
+707
New +$1.72M
NVET
13
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$528K 0.46%
+154,840
New +$611K
ALDX icon
14
Aldeyra Therapeutics
ALDX
$92.9M
$428K 0.37%
+63,146
New +$424K
EPIX
15
DELISTED
ESSA Pharma
EPIX
$119K 0.1%
+1,405
New +$147K

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Boxer Capital, which disclosed 15 positions worth $116M. Its ten largest holdings account for 96% of the portfolio.

Its largest position is Mirati Therapeutics, Inc. Common Stock: 2,023,232 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets.

  • Boxer Capital's largest Q4 2015 buy was Mirati Therapeutics, Inc. Common Stock: 2,023,232 shares worth $63.9M.
  • Boxer Capital's ten largest holdings make up 96% of its $116M portfolio in Q4 2015.
  • Boxer Capital disclosed 15 positions in Q4 2015, its first 13F filing on record.

Based on Boxer Capital's 13F filing for Q4 2015, filed 16 Feb 2016.